PT - JOURNAL ARTICLE AU - Wei, Xiaolin AU - Liang, Dabin AU - Zhang, Zhitong AU - Thorpe, Kevin AU - Zhou, Lingyun AU - Zhao, Jinming AU - Qin, Huifang AU - Liang, Xiaoyan AU - Cui, Zhezhe AU - Huang, Yan AU - Huang, Liwen AU - Lin, Mei TI - Active case finding using mobile vans equipped with artificial intelligence aided radiology tests and sputum collection for rapid diagnostic tests to reduce tuberculosis prevalence in rural China: protocol for a pragmatic trial AID - 10.1101/2024.12.08.24318678 DP - 2024 Jan 01 TA - medRxiv PG - 2024.12.08.24318678 4099 - http://medrxiv.org/content/early/2024/12/08/2024.12.08.24318678.short 4100 - http://medrxiv.org/content/early/2024/12/08/2024.12.08.24318678.full AB - Background Tuberculosis (TB) remains a significant public health challenge, particularly in rural areas of high-burden countries like China. Active case finding (ACF) and timely treatment has been proved effective in reducing TB prevalence but it is still unknown regarding the impact on TB epidemic when employing new technologies in ACF. This study aims to evaluate the effectiveness of a comprehensive ACF package utilizing mobile vans equipped with artificial intelligence (AI)-aided radiology, and GeneXpert testing in reducing TB prevalence among high-risk populations in rural Guangxi, China.Methods A pragmatic cluster randomized controlled trial will be conducted in two counties of Guangxi, China. The trial will randomize 23 townships to intervention or control groups at 1:1 ratio. The intervention group will receive a single ACF campaign in Year 1, incorporating mobile vans, AI-based DR screening, symptom assessment, and sputum collection for GeneXpert testing. Control group participants will receive usual care. TB patients identified in Year 1 will be required to complete TB treatment in Year 2. The primary outcome is the prevalence rate of bacteriologically confirmed TB among high-risk populations in Year 3. Process evaluation will explore adaption, acceptability and feasibility of the intervention. We will conduct incremental costing study to inform future scale-up of the intervention in other settings.Discussion This study will provide valuable insights into the effectiveness and feasibility of utilizing AI, mobile vans and GeneXpert for TB ACF to reduce TB prevalence in rural settings. If successful, this model will contribute to possible solutions to achieve the WHO End TB Strategy by 2035.Trial registration: ClinicalTrials.gov Identifier -NCT06702774Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier -NCT06702774Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has obtained ethical approval from the Guangxi Institutional Review Board of the Guangxi CDC on 26 August 2021 (Ref: GXIRB2021-0033).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesMetadata won’t be publicly available due to local policy. Clustered data can be shared by email (Guangxi CDC, lxy530028{at}163.com) based on reasonable request for research purpose only upon approval after January 1, 2027.AIArtificial IntelligenceAIDSAcquired Immunodeficiency SyndromeCDCCenter for Disease Prevention and ControlDMCData Monitoring CommitteeDRDigital RadiographyHIVHuman immunodeficiency VirusMDR-TBMultidrug-resistant TuberculosisNTPNational TB ProgramRCT/cRCTRandomised Controlled Trial/Cluster Randomised Controlled TrialTBTuberculosisTCSTrial Steering CommitteeTMUTrial Management UnitWHOWorld Health Organization